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Background: Patients with cancer of unknown primary account for 10% of patients with metastatic spinal cord
compression (MSCC). This retrospective study was performed to identify prognostic factors for functional outcome,
local control of MSCC, and survival in 175 of such patients treated with radiotherapy alone.
Methods: Investigated were nine potential prognostic factors including age, gender, Eastern Cooperative Oncology
Group performance score (ECOG-PS), number of involved vertebrae, pre-radiotherapy ambulatory status, other bone
metastases, visceral metastases, time developing motor deficits before radiotherapy, and the radiation schedule.
Results: On multivariate analysis, better functional outcome was associated with absence of visceral metastases
(estimate: 0.72; 95%-confidence interval [CI]: 0.07-1.36; p = 0.030) and a slower (>7 days) development of motor
deficits (estimate: 1.93; 95%-CI: 1.18-2.68; p< 0.001). Improved local control of MSCC was associated with absence of
visceral metastases (risk ratio [RR]: 10.26; 95%-CI: 2.11-74.73; p = 0.004). Improved survival was associated with
favorable ECOG-PS (RR: 2.12; 95%-CI: 1.40-3.29; p< 0.001), being ambulatory prior to radiotherapy (RR: 1.98; 95%-CI:
1.40-2.81; p< 0.001), absence of visceral metastases (RR: 2.74; 95%-CI: 1.93-3.91; p< 0.001), and slower development
of motor deficits (RR: 1.27; 95%-CI: 1.07-1.51; p = 0.007). Absence of other bone metastases showed a trend (RR: 1.38;
95%-CI: 0.98-1.95; p = 0.07).
Conclusions: This study identified additional independent prognostic factors for functional outcome, local control
of MSCC, and survival after radiotherapy of MSCC from cancer of unknown primary. These prognostic factors can
help select the best treatment regimen for each individual patient.
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treatment outcomesBackground
Up to 10% of adult cancer patients develop metastatic
spinal cord compression (MSCC) during their disease
[1,2]. Today the most common treatment modality used
for MSCC is radiotherapy alone. The addition of upfront
decompressive surgery to radiotherapy can improve the
outcomes of those 10-15% of patients with MSCC, who
have a favorable ECOG-PS, a relatively good survival
prognosis, and a limited number of involved vertebrae
[2,3]. To optimally take into account each patient’s indi-
vidual situation, it is mandatory to personalize the* Correspondence: rades.dirk@gmx.net
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reproduction in any medium, provided the ortreatment approach as much as possible. Personalization
of treatment can be facilitated if patients with MSCC
from a particular type of primary tumor are regarded as
a separate group of patients. Such an approach appears
reasonable, because tumor entities can vary a lot regard-
ing the prognosis of the disease and the biological be-
havior. Patients with MSCC from cancer of unknown
primary demand particular attention, because they have
a very poor survival prognosis when compared to
patients with MSCC from other tumors [1,2]. Further-
more, these patients are relatively common and account
for about 10% of all patients developing MSCC. This
study aimed to identify independent prognostic factors
for different endpoints including functional outcome,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.










≤65 years (n = 85) 9 (11) 53 (62) 23 (27)
>65 years (n = 90) 12 (13) 43 (48) 35 (39) 0.54
Gender
Female (n = 53) 8 (15) 27 (51) 18 (34)
Male (n = 122) 13 (11) 69 (57) 40 (33) 0.42
ECOG performance score
2 (n = 49) 10 (20) 29 (59) 10 (20)
3-4 (n = 126) 11 (9) 67 (53) 48 (38) 0.25
Number of involved vertebrae
1-2 (n = 55) 8 (15) 35 (64) 12 (22)
≥3 (n = 120) 13 (11) 61 (51) 46 (38) 0.84
Ambulatory status prior to RT
Not Ambulatory
(n = 89)
9 (10) 46 (52) 34 (38)
Ambulatory (n = 86) 12 (14) 50 (58) 24 (28) 0.21
Other bone metastases
No (n = 65) 11 (17) 39 (60) 15 (23)
Yes (n = 110) 10 (9) 57 (52) 43 (39) 0.46
Visceral metastases
No (n = 86) 15 (17) 34 (40) 37 (43)
Yes (n = 89) 6 (7) 62 (70) 21 (24) 0.030
Time developing motor deficits
1-7 days (n = 88) 4 (5) 38 (43) 46 (52)




7 (8) 60 (67) 23 (26)
Longer-course RT
(n = 85)
14 (16) 36 (42) 35 (41) 0.86
Entire cohort (n = 175) 21 (12) 96 (55) 58 (33)
The p-values were obtained from the multivariate analysis performed with the
ordered-logit model.
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of patients with MSCC from cancer of unknown primary
reported so far, in order to contribute to the
personalization of the treatment of these patients.
Results
Of the 175 patients included in this study, 21 (12%)
showed an improvement, 96 (55%) no further progres-
sion (no change), and 58 (33%) deterioration of motor
function (21% real deterioration plus 12% no improve-
ment of complete paraplegia). Summarized in Table 1 are
the results of the multivariate analysis of functional out-
come. An improvement of motor function was signifi-
cantly associated with absence of visceral metastases at
the time of radiotherapy (estimate: 0.72; 95%-confidence
interval [CI]: 0.07-1.36; p = 0.030) and slower (>7 days)
development of motor deficits prior to the start of radio-
therapy (estimate: 1.93; 95%-CI: 1.18-2.68; p< 0.001).
An improvement of local control of MSCC was asso-
ciated with the absence of visceral metastases at the time
of radiotherapy (p = 0.001) in the univariate analysis. The
results of the univariate analysis are summarized in
Table 2. On multivariate analysis, improved local control
was also significantly associated with absence of visceral
metastases (risk ratio [RR]: 10.26; 95%-CI: 2.11-74.73;
p = 0.004).
The median survival time was 4 months in the entire
cohort (Figure 1). According to the univariate analysis of
survival, improvement was associated with age
<65 years (p = 0.048), an ECOG-PS 2 (p< 0.001), being
ambulatory prior to radiotherapy (p< 0.001), absence of
other bone metastases at the time of radiotherapy
(p = 0.005), absence of visceral metastases at the time of
radiotherapy (p< 0.001), and slower development of
motor deficits prior to radiotherapy (p< 0.001). The
results of the univariate analysis of survival are summar-
ized in Table 3. The multivariate analysis revealed four
prognostic factors to be associated with improvement
of survival: ECOG-PS 2 (RR: 2.12, 95%-CI: 1.40–3.29,
p < 0.001), being ambulatory (RR: 1.98, 95%-CI: 1.40–
2.81, p < 0.001), the absence of visceral metastases (RR:
2.74, 95%-CI: 1.93–3.91, p< 0.001) and the time devel-
oping motor deficits (RR: 1.27, 95%-CI: 1.07–1.51,
p = 0.007). Absence of other bone metastases showed a
trend (RR: 1.38; 95%-CI: 0.98-1.95; p = 0.07). The
results of the multivariate analysis of survival are
shown in Table 4.
Acute radiation induced toxicity such as skin toxicity,
nausea and diarrhea was mild, late toxicity such as myel-
opathy was not observed.
Discussion
The treatment for patients with MSCC should be
planned by taking into account independent prognosticfactors, which allow estimating the patient’s prognosis.
Prognostic factors that indicate the effect of radiotherapy
on functional outcome are important to identify patients
who appear adequately treated with radiotherapy alone,
i.e. patients who have a high probability to maintain or
regain the ability to walk after irradiation. Such prognos-
tic factors can also identify patients who do not achieve
a satisfying functional outcome with radiotherapy alone
and, therefore, could benefit from upfront decompres-
sive surgery in addition to radiotherapy. In randomized
study of 101 highly selected patients that compared
decompressive surgery followed by radiotherapy to
radiotherapy alone, significantly more patients were able







≤65 years (n = 85) 95 95
>65 years (n = 90) 92 61 0.13
Gender
Female (n = 53) 96 96
Male (n = 122) 92 75 0.35
ECOG performance score
2 (n = 49) 98 83
3-4 (n = 126) 88 88 0.44
Number of involved vertebrae
1-2 (n = 55) 98 82
≥3 (n = 120) 90 82 0.27
Ambulatory status prior to RT
Not Ambulatory (n = 89) 92 92
Ambulatory (n = 86) 93 80 0.54
Other bone metastases
No (n = 65) 98 79
Yes (n = 110) 88 88 0.55
Visceral metastases
No (n = 86) 98 91
Yes (n = 89) 86 43 0.002
Time developing motor deficits
1-7 days (n = 88) 89 89
>7 days (n = 87) 96 83 0.22
Radiation schedule
Short-course RT (n= 90) 87 77
Longer-course RT (n= 85) 98 86 0.12
Entire cohort (n = 175) 93 82
Figure 1 Overall survival of the entire cohort (Kaplan-Meier
curve).







≤65 years (n = 85) 32 8
>65 years (n = 90) 19 12 0.048
Gender
Female (n = 53) 26 13
Male (n = 122) 25 8 0.38
ECOG performance score
2 (n = 49) 53 24
3-4 (n = 126) 14 4 <0.001
Number of involved vertebrae
1-2 (n = 55) 33 9
≥3 (n = 120) 22 10 0.13
Ambulatory status prior to RT
Not Ambulatory (n = 89) 15 3
Ambulatory (n = 86) 36 17 <0.001
Other bone metastases
No (n = 65) 38 15
Yes (n = 110) 17 7 0.005
Visceral metastases
No (n = 86) 45 16
Yes (n = 89) 6 3 <0.001
Time developing motor deficits
1-7 days (n = 88) 10 1
>7 days (n = 87) 40 18 <0.001
Radiation schedule
Short-course RT (n= 90) 21 11
Longer-course RT (n= 85) 29 8 0.19
Entire cohort (n = 175) 25 9
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group (84% vs. 57%, p = 0.001) [3].
To be able to predict the patient’s survival prognosis
is also very important for the selection of the appro-
priate treatment regimen. Patients with a more favor-
able prognosis are likely to benefit from longer-course
radiotherapy programs supplemented by bisphospho-
nate treatment rather than from short-course radio-
therapy. This is because short-course radiotherapy
results in worse local control of MSCC, which becomes
more of an issue in patients surviving 6 months or
longer following treatment [4,5]. Prognostic factors
that allow predict survival are important also for identi-
fying patients with a very poor survival prognosis, for
whom a short-course radiotherapy would be a better
option in order to avoid unnecessary distress for these
often debilitated patients.
Table 4 Multivariate analysis of survival (Cox
proportional hazards model)




(≤65 vs. >65 years) 1.14 0.83 – 1.58 0.42
ECOG performance score
(2 vs. 3–4) 2.12 1.40 – 3.29 <0.001
Ambulatory status prior to RT
(ambulatory vs. ot ambulatory) 1.98 1.40 – 2.81 <0.001
Other bone metastases
(no vs. yes) 1.38 0.98 – 1.95 0.07
Visceral metastases
(no vs. yes) 2.74 1.93 – 3.91 <0.001
Time developing motor deficits
(>7 vs. 1–7 days 1.27 1.07 – 1.51 0.007
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functional outcome and survival, because both endpoints
are important in order to choose the most appropriate
treatment regimen for the individual patient with MSCC
from cancer of unknown primary. The multivariate ana-
lysis of functional outcome revealed that patients who
had visceral metastases at the time of radiotherapy and
experienced a rapid development of motor deficits prior
to radiotherapy had an unfavorable functional outcome.
These findings agree with our previous report on MSCC
from cancer of unknown primary published five years
ago [6]. The finding that a rapid development of motor
deficits was associated with a worse functional outcome
could be explained by the fact that a rapid decline in
motor function was caused by disruption of the arterial
blood flow resulting in spinal cord infarction [7,8]. In
contrast, a slower decline in motor function was most
likely a result of venous congestion, which was reversible
in many cases. In our present study, 21% of the patients
showed a deterioration of motor function after radiother-
apy alone, and 12% did not improve after complete para-
plegia. In a recent retrospective study of 51 patients who
received surgical management of MSCC from CUP, de-
terioration was observed only in 6% of patients [9].
Therefore, it appears that a considerable proportion of
patients with MSCC from cancer of unknown primary
may be considered for decompressive surgery, in particu-
lar those patients with a rapid development of motor
deficits or visceral metastases who do not have an extra-
ordinarily poor survival prognosis.
Prognostic factors predicting the patient’s survival
prognosis are important in two ways. They can help
identify patients who may not be candidates for decom-
pressive surgery because they have a very poor survival
prognosis, although functional outcome followingradiotherapy alone is not expected to be satisfying. Fur-
thermore, the estimated survival time has an impact on
the selection of the radiotherapy regimen. In the present
study, survival was negatively associated with four prog-
nostic factors indicating an advanced and rapidly pro-
gressing disease: poor performance status, being not
ambulatory prior to radiotherapy, presence of visceral
metastases, and rapid development of motor deficits
prior to radiotherapy. Patients with these negative pre-
dictors may receive short-course radiotherapy to avoid
that these patients have to spend a considerable part of
their remaining life time with treatment. In the group of
patients (n = 28) with all four negative prognostic factors,
the 6-month survival rate was only 4%. These patients
may be candidates for single-fraction radiotherapy or
best supportive care.
The prognostic value of the ECOG-PS has not been
observed in our previous study published five years ago
and can, therefore, be considered a new prognostic fac-
tor for patients with MSCC from cancer of unknown
primary [6]. Potential prognostic factors for local control
of MSCC have not yet been investigated in patients with
MSCC from cancer of unknown primary at all. There-
fore, the present study provides new and important
results in addition to our previous report. However, the
retrospective nature of this study must be taken into ac-
count during the interpretation of the results. Retro-
spective studies always bear the risk of hidden selection
biases. However, a prospective study will be difficult to
perform in patients with MSCC from cancer of un-
known primary, as it will take several years to include a
sufficiently large number of such patients.
Conclusions
The present study identified independent prognostic fac-
tors for functional outcome, local control of MSCC, and
survival in patients with MSCC from cancer of unknown
primary. These prognostic factors can guide physicians
to decide which is the most appropriate treatment regi-
men for the individual patient. During such a decision
making process the questions whether decompressive
surgery may be a reasonable option and whether short-
course or longer-course radiotherapy is more appropri-
ate should be adressed.
Methods
The data of 175 patients irradiated for MSCC from can-
cer of unknown primary between 1991 and 2011 were
retrospectively reviewed. The patients had to fulfill the
following criteria to be included in this analysis: motor
deficits of the lower extremities caused by metastatic
compression of the thoracic or lumbar spinal cord,
confirmation of the diagnosis with spinal computed
tomography or magnet resonance imaging, and no
Table 5 Patient characteristics
N patients Proportion (%)
Age
≤65 years 85 49







Number of involved vertebrae
1-2 55 31
≥3 120 69
Ambulatory status prior to RT








Time developing motor deficits
1-7 days 88 50
>7 days 87 50
Radiation schedule
Short-course RT 90 51
Longer-course RT 85 49
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parts of the spinal cord. The patients were given a daily
dexamethasone dose between 3x4 mg and 4x8 mg from
the first day of radiotherapy and then at least for another
week. The patients were generally presented to a neuro-
surgeon or an orthopedic surgeon to discuss whether
upfront decompressive surgery may be a reasonable op-
tion or not. Patients were generally not considered for
surgery if they had a poor performance status (ECOG
3–4), involvement of several spinal sites, severe neuro-
logic deficits (paraplegia) for longer than 48 hours, and a
poor expected survival in case of multiple extraosseous
lesions. Only 10% of the patients who presented with
MSCC from CUP were considered candidates for sur-
gery. The data were collected from the patients them-
selves, their files, and their general practitioners or
treating oncologists. Because this study did not report
on a clinical trial, and because the data were retrospect-
ive in nature and analyzed anonymously, approval by an
ethic committee was not necessary. The patient charac-
teristics are summarized in Table 5.
Every participating center contributed an unselected
series of patients with MSCC treated within a specific
time period. The energy used for irradiation varied be-
tween 6–10 MeV photons, and the planning target vol-
ume included one uninvolved vertebra above and below
the metastatic lesions. Motor function was assessed right
before the start of radiotherapy, as well as at one month,
three months and six months after radiotherapy was
completed. To categorize motor function we used a 5-
point scale: Grade 0: normal strength; Grade 1: ambula-
tory without aid, Grade 2: ambulatory with aid, Grade 3:
not ambulatory, Grade 4: paraplegia [10]. If the patient’s
motor function was rated as improved or deteriorated,
an alteration of at least one point on the 5-point scale
must have had occurred. Patients who presented with
complete paraplegia and did not approve were rated as
deteriorated.
The following nine potential prognostic factors were
investigated with respect to post-radiotherapy motor
function, local control of MSCC, and survival: age (≤65
vs. >65 years), gender, Eastern Cooperative Oncology
Group performance score (ECOG-PS 2 vs. 3–4), number
of involved vertebrae (1–2 vs. 3), pre-radiotherapy am-
bulatory status (not ambulatory vs. ambulatory), other
bone metastases at the time of radiotherapy (no vs. yes),
visceral metastases at the time of radiotherapy (no vs.
yes), time developing motor deficits before radiotherapy
(1–7 vs. >7 days), and the radiotherapy schedule (short-
course radiotherapy with 1x8 Gy or 5x4 Gy in 1 week vs.
longer-course radiotherapy with 10x3 Gy in 2 weeks,
15x2.5 Gy in 3 weeks, or 20x2 Gy in 4 weeks).
The nine potential prognostic factors for functional
outcome were included in a multivariate analysisperformed with the ordered-logit model, because these
data were ordinal (−1 = deterioration, 0 = no change,
1 = improvement of motor function). Local control was
defined as no recurrence or progression of MSCC in the
irradiated spinal region. The diagnosis of an in-field re-
currence of MSCC was confirmed by computed tomog-
raphy or magnet resonance imaging. Local control and
survival rates were calculated with the Kaplan-Meier-
method [11]. The differences between the Kaplan-Meier
curves were calculated with the log-rank test. The prog-
nostic factors found to be significant (p< 0.05) in the
univariate analysis were included in a multivariate ana-
lysis, performed with the Cox proportion hazards model.
Patients were followed until death or for median
7.5 months (range: 6–20 months) in those alive at the
last follow-up visit.Abbreviations
ECOG: Eastern cooperative oncology group; ECOG-PS: Eastern cooperative
oncology group performance score; Gy: Gray; MeV: Mega electron volts;
MSCC: Metastatic spinal cord compression; RT: Radiotherapy.
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